Latest news with #HealthTechnologyAssessment
Qatar Tribune
2 days ago
- Health
- Qatar Tribune
MoPH strengthens health technology assessment in Qatar
DOHA: The Ministry of Public Health (MoPH) has highlighted its commitment to strengthening national capabilities in Health Technology Assessment (HTA) and health policy, having established a dedicated national unit in this field and developed a comprehensive assessment framework with clear standards. These efforts come as part of the twelfth outcome, "Excellence in Health Research, Development, and Innovation," under the third priority, "Efficiency and Resilience of the Health System," in the National Health Strategy 2024–2030. In that context, the MoPH has recently organized a high-level workshop to enhance national capacities in HTA and health policy, in collaboration with the London School of Economics and Political Science (LSE) and Hoffmann-La Roche. The workshop formed part of the Ministry's ongoing efforts to entrench evidence-based decision-making across healthcare sectors and to promote long-term sustainability and resilience within Qatar's health system. The workshop reflected the MoPH's commitment to ensuring the effective and equitable allocation of health resources, supporting innovation through effective governance of emerging technologies, and enhancing the overall resilience and sustainability of the health system. It also underscored the importance of multi-sectoral partnerships in achieving national health priorities. These efforts align with the goals of the Human Development Pillar of Qatar National Vision 2030 and the priorities of the National Health Strategy, particularly in building a high-performing, efficient, person-centered, data-driven health system that is responsive to current and future health needs. The workshop was opened by Head of the National Health Technology Assessment Unit Project within the National Health Strategy at the MoPH Dr Anas Hamad emphasized the importance of concerted efforts to achieve the Ministry's objectives under its 2024–2030 strategy, improve health system outcomes, and build specialized national capacities in this field. Dr Hamad said: "The project to establish a national HTA unit is based on the third priority of the National Health Strategy, which focuses on efficiency and resilience, and is part of the twelfth outcome relating to excellence in research, development, and innovation. The HTA project is a pivotal initiative to develop an integrated and reliable framework to support transparent, evidence-based decision-making within Qatar's health system. Through systematic evaluation of the clinical, economic, and social impacts of modern health technologies, we aim to ensure the best health value for citizens and residents, and to enhance the sustainability of Qatar's health system. This workshop is a foundational step for this project, which will contribute to achieving a sustainable, high-quality, efficient, patient-centered, and prudent health system that meets the needs of current and future generations." In turn, General Manager of Hoffmann-La Roche in the Gulf region Dr Ahmed Tawfiq stressed the importance of unifying efforts between the public and private sectors to develop sustainability frameworks aligned with shared objectives. Dr Tawfiq said: "Today, we are working with our partners at the Ministry of Public Health and the London School of Economics and Political Science to achieve a shared goal of improving healthcare in Qatar, in line with Qatar National Vision 2030. By building capacity in health technology assessment, we ensure that the right treatments reach the right patients at the right time, relying on the latest scientific evidence and modern technologies." Chair in Health Policy and Director of the LSE Health Centre at the London School of Economics and Political Science Professor Elias Mossialos said: "The LSE is proud to deliver an intensive two-day training program for the Ministry of Public Health in Qatar, focusing on key trends in healthcare, disease prevention and early diagnosis, and economic evaluation in healthcare as an essential tool for improving system performance and decision-making, in addition to HTA programs and value-based frameworks introduced by health innovations." The workshop provided participants with a comprehensive and in-depth understanding of the frameworks, capabilities, and key factors required to build an effective HTA structure. The focus was on applying real-world evidence to inform policy and investment decisions, and laying the foundation for the systematic and organized use of economic evaluation within Qatar's health policy framework.
Qatar Tribune
3 days ago
- Health
- Qatar Tribune
MoPH boosts health tech assessment in Qatar
Tribune News Network Doha The Ministry of Public Health (MoPH) recently organised a high-level workshop to enhance national capacities in Health Technology Assessment (HTA) and health policy in collaboration with the London School of Economics and Political Science (LSE) and Hoffmann-La Roche. The workshop formed part of the ministry's ongoing efforts to entrench evidence-based decision-making across healthcare sectors and to promote long-term sustainability and resilience within Qatar's health system. The workshop aimed to strengthen national capabilities in HTA and health policy. Establishing a dedicated national unit in this field and developing a comprehensive assessment framework with clear standards are part of the twelfth outcome, 'Excellence in Health Research, Development, and Innovation,' under the third priority, 'Efficiency and Resilience of the Health System,' in the National Health Strategy 2024–2030. The workshop reflected the ministry's commitment to ensuring the effective and equitable allocation of health resources, supporting innovation through effective governance of emerging technologies, and enhancing the overall resilience and sustainability of the health system. It also underscored the importance of multi-sectoral partnerships in achieving national health priorities. These efforts align with the goals of the Human Development Pillar of Qatar National Vision 2030 and the priorities of the National Health Strategy, particularly in building a high-performing, efficient, person-centred, data-driven health system that is responsive to current and future health needs. The workshop was opened by Dr Anas Hamad, head of the National Health Technology Assessment Unit Project within the National Health Strategy at the Ministry of Public Health, who emphasised the importance of concerted efforts to achieve the ministry's objectives under its 2024–2030 strategy, improve health system outcomes, and build specialised national capacities in this field. He said, 'The project to establish a national Health Technology Assessment (HTA) unit is based on the third priority of the National Health Strategy, which focuses on efficiency and resilience, and is part of the twelfth outcome relating to excellence in research, development, and innovation. The HTA project is a pivotal initiative to develop an integrated and reliable framework to support transparent, evidence-based decision-making within Qatar's health system. 'Through systematic evaluation of the clinical, economic, and social impacts of modern health technologies, we aim to ensure the best health value for citizens and residents, and to enhance the sustainability of Qatar's health system. This workshop is a foundational step for this project, which will contribute to achieving a sustainable, high-quality, efficient, patient-centred, and prudent health system that meets the needs of current and future generations.' Dr Ahmed Tawfiq, general manager of Hoffmann-La Roche in the Gulf region, stressed the importance of unifying efforts between the public and private sectors to develop sustainability frameworks aligned with shared objectives. He said, 'Today, we are working with our partners at the Ministry of Public Health and the London School of Economics and Political Science to achieve a shared goal of improving healthcare in Qatar, in line with Qatar National Vision 2030. By building capacity in health technology assessment, we ensure that the right treatments reach the right patients at the right time, relying on the latest scientific evidence and modern technologies.' Professor Elias Mossialos, chair in Health Policy and director of the LSE Health Centre at the London School of Economics and Political Science, said: 'The LSE is proud to deliver an intensive two-day training programme for the Ministry of Public Health in Qatar, focusing on key trends in healthcare, disease prevention and early diagnosis, and economic evaluation in healthcare as an essential tool for improving system performance and decision-making, in addition to HTA programmes and value-based frameworks introduced by health innovations.' Through lectures and discussions over two days, delivered and moderated by Professor Elias Mossialos, Dr Panos Kanavos, and Dr Alex Carter, the workshop provided participants with a comprehensive and in-depth understanding of the frameworks, capabilities, and key factors required to build an effective HTA structure. The focus was on applying real-world evidence to inform policy and investment decisions, and laying the foundation for the systematic and organised use of economic evaluation within Qatar's health policy framework.
Cision Canada
29-05-2025
- Health
- Cision Canada
A joint study by Duchesnay and PeriPharm exposes critical gaps in access to innovative women's health products in Canada
The research reveals the challenges of introducing innovative medications in women's health in Canada BLAINVILLE, QC, May 29, 2025 /CNW/ - Duchesnay, member of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life Sciences Innovation Award by ADRIQ, in collaboration with PeriPharm, is proud to announce the results of a landmark study exploring the accessibility of innovative women's health products in Canada. The research exposes systemic gaps and significant barriers that prevent Canadian women from accessing the innovative therapies they need. The study found that of the 45 women's health products approved by the U.S. Food and Drug Administration (FDA) from January 1, 2003, to December 31, 2023, only 24 (53%) had received regulatory approval by Health Canada as of July 2024 and only 13 of these products are currently reimbursed publicly. 1 "These findings highlight a clear need to address inequities in how women's health is assessed, valued and prioritized," said Dany Hallé, Vice president, Commercial Affairs, DPG. "Striving to shape women's health ecosystem in Canada, we, at Duchesnay, believe that Canadian women deserve to have timely access to healthcare innovations." Another important issue highlighted by researchers is the delays Canadian women face when it comes to approval and reimbursement processes for women's health therapies. Compared to the general access timeline for medications in Canada, the process for obtaining public coverage listing for women's health medications takes one year longer and can even exceed three years. The study suggests that the current evidence-based Health Technology Assessment (HTA) framework may not fully capture the added value of innovative drugs in women's health, potentially contributing to delays or barriers in reimbursement and market access. "This is a call to action," said Catherine Beauchemin, Ph.D., partner at PeriPharm. "This initiative marks an important first step toward improving access to innovations in women's health. To advance women's health outcomes in Canada, we must start by understanding their needs and preferences." This study will serve as a benchmark and lay the groundwork for the development of a position paper co-written by leading experts in the domain addressing the challenges women ultimately face in the assessment of innovative medicines in Canada. This white paper would be hopefully available by year end. 1 In comparison, based on data between 2016 and 2020, 67% of all new active substance approval by FDA and/or EMA have been submitted to Health Canada. ABOUT PERIPHARM Founded in 2003, PeriPharm is a Canadian company specializing in pharmacoeconomics and outcomes research. The company's mission is to provide high-quality, diversified services to ensure optimal market access of health care innovations. PeriPharm's activity is built on the belief the best available therapies should be accessible to those who need it. As a leader in the field of health economics and data generation, PeriPharm has contributed to the success of several market access initiatives. For more information about PeriPharm, please visit Follow us on LinkedIn. ABOUT DUCHESNAY Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. Until recently, the company focused on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Today, Duchesnay has broadened its portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at different stages of their lives. Believing that women around the world deserve to have access to specialized treatments for their conditions, Duchesnay now distributes its products internationally. For more information about Duchesnay, please visit Follow us on LinkedIn. ABOUT DUCHESNAY PHARMACEUTICAL GROUP Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy. DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem. DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations.
Associated Press
29-05-2025
- Business
- Associated Press
A joint study by Duchesnay and PeriPharm exposes critical gaps in access to innovative women's health products in Canada
The research reveals the challenges of introducing innovative medications in women's health in Canada BLAINVILLE, QC, May 29, 2025 /PRNewswire/ - Duchesnay, member of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life Sciences Innovation Award by ADRIQ, in collaboration with PeriPharm, is proud to announce the results of a landmark study exploring the accessibility of innovative women's health products in Canada. The research exposes systemic gaps and significant barriers that prevent Canadian women from accessing the innovative therapies they need. The study found that of the 45 women's health products approved by the U.S. Food and Drug Administration (FDA) from January 1, 2003, to December 31, 2023, only 24 (53%) had received regulatory approval by Health Canada as of July 2024 and only 13 of these products are currently reimbursed publicly.1 'These findings highlight a clear need to address inequities in how women's health is assessed, valued and prioritized,' said Dany Hallé, Vice president, Commercial Affairs, DPG. 'Striving to shape women's health ecosystem in Canada, we, at Duchesnay, believe that Canadian women deserve to have timely access to healthcare innovations.' Another important issue highlighted by researchers is the delays Canadian women face when it comes to approval and reimbursement processes for women's health therapies. Compared to the general access timeline for medications in Canada, the process for obtaining public coverage listing for women's health medications takes one year longer and can even exceed three years. The study suggests that the current evidence-based Health Technology Assessment (HTA) framework may not fully capture the added value of innovative drugs in women's health, potentially contributing to delays or barriers in reimbursement and market access. 'This is a call to action,' said Catherine Beauchemin, Ph.D., partner at PeriPharm. 'This initiative marks an important first step toward improving access to innovations in women's health. To advance women's health outcomes in Canada, we must start by understanding their needs and preferences.' This study will serve as a benchmark and lay the groundwork for the development of a position paper co-written by leading experts in the domain addressing the challenges women ultimately face in the assessment of innovative medicines in Canada. This white paper would be hopefully available by year end. ABOUT PERIPHARM Founded in 2003, PeriPharm is a Canadian company specializing in pharmacoeconomics and outcomes research. The company's mission is to provide high-quality, diversified services to ensure optimal market access of health care innovations. PeriPharm's activity is built on the belief the best available therapies should be accessible to those who need it. As a leader in the field of health economics and data generation, PeriPharm has contributed to the success of several market access initiatives. For more information about PeriPharm, please visit . Follow us on LinkedIn. ABOUT DUCHESNAY Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. Until recently, the company focused on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Today, Duchesnay has broadened its portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at different stages of their lives. Believing that women around the world deserve to have access to specialized treatments for their conditions, Duchesnay now distributes its products internationally. For more information about Duchesnay, please visit . Follow us on LinkedIn. ABOUT DUCHESNAY PHARMACEUTICAL GROUP Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy. DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem. DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations. For more information, please visit Follow us on LinkedIn. View original content to download multimedia: SOURCE Duchesnay inc.
Khaleej Times
21-04-2025
- Health
- Khaleej Times
ISPOR UAE Chapter and AbbVie announce intent to collaborate on healthcare advancement
The ISPOR UAE Chapter, the local chapter of the leading international scientific and educational organization for health economics and outcomes research (HEOR), and AbbVie, a global biopharmaceutical company, have announced their intent to explore collaborative opportunities aimed at enhancing healthcare outcomes in the UAE. The Letter of Intent (LOI) was signed during the Abu Dhabi Global Health Week in the presence of senior board members from the ISPOR UAE Chapter and senior leadership from AbbVie Gulf. The LOI signifies a mutual commitment to work together in key areas including Health Technology Assessment (HTA) and policy shaping, as well as research and evidence generation. This collaboration aims to leverage the ISPOR UAE Chapter's extensive network and knowledge in HEOR and AbbVie's scientific expertise to contribute to a more robust and evidence-based healthcare system in the UAE. Prof. Nadia Al Mazrouei, ISPOR UAE Chapter President, emphasised that 'The ISPOR UAE Chapter is dedicated to fostering excellence in health economics and outcomes research to inform healthcare decisions in the UAE. This Letter of Intent with AbbVie, formalized during the prestigious Abu Dhabi Global Health Week, marks an important step in bridging our network of researchers, policymakers, and healthcare professionals with industry expertise. We are enthusiastic about the potential of this collaboration to generate impactful research and contribute to the development of evidence-based policies that benefit patients across the UAE.' Elhussein Abdellatif, General Manager Gulf Levant AbbVie, stated, 'We are proud to reaffirm our commitment to elevating the standards of care and enhancing patients' lives. We understand the vital importance of Health Technology Assessment (HTA) and health policy in supporting access to essential therapies. Our collaboration with the ISPOR UAE Chapter provides us with an opportunity to share our expertise and collectively advance toward a more sustainable and patient-focused healthcare ecosystem in the UAE.'
